Evidence map›Paper›PMID 35181744›Full record

Trial reportBone marrow transplantation2022

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.

Saskia Hell, Madlen Jentzsch, Georg-Nikolaus Franke, Nadja Jäkel, Susann Schulze, Jeanett Edelmann, Kolja Nenoff, Nora Grieb, Veljko Jeremic, Michael Cross and 9 more

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Saskia HellLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Madlen JentzschLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Georg-Nikolaus FrankeLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.ORCID 0000-0001-8239-002X
Nadja JäkelDepartment of Hematology/Oncology, University Hospital Halle, Halle (Saale), Germany.
Susann SchulzeKrukenberg Cancer Center, University Halle, Halle (Saale), Germany.
Jeanett EdelmannLeipzig Medical Center, Institute of Legal Medicine, University Leipzig, Leipzig, Germany.
Kolja NenoffLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Nora GriebLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Veljko JeremicDepartment for Operations Research and Statistics, Faculty of Organizational Sciences, University of Belgrade, Belgrade, Serbia.
Michael CrossLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Sabine LeibleinLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Enrica BachLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Wolfram PönischLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Haifa-Kathrin Al-AliKrukenberg Cancer Center, University Halle, Halle (Saale), Germany.ORCID 0000-0001-5009-2239
Sebastian SchwindLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.ORCID 0000-0002-1315-2332
Uwe PlatzbeckerLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Thoralf LangeLeipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.
Dietger Niederwieser *Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany.ORCID 0000-0002-4737-1103
Vladan Vucinic *Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany. vladan.vucinic@medizin.uni-leipzig.de.ORCID 0000-0002-8398-285X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChimerismHematopoietic Stem Cell TransplantationHumansImmunosuppression TherapyProspective StudiesTransplantation ChimeraTransplantation Conditioning

Identifiers

PMID35181744
PMCPMC9090627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.